Clinical trials: Hepatobiliary Disorders
Advanced Chronic Liver Disease, Portal Hypertension Related to Cirrhosis
Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease
This study aims to implement measures to avoid the use of NSAIDs or metamizole in patients with advanced chronic liver disease (ACLD) scheduled for major surgery, which are contraindicated due to increased risk of renal…
- Trial name
- NCT07249294
- Testing
- Multidisciplinary support program
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Parc de Salut Mar
Nonalcoholic Fatty Liver
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
- Trial name
- NCT03763877
- Testing
- PXL770
- Where
- 15 sites in United States
- Volunteers
- 121 people
- Sponsor
- Poxel SA
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Liver Cancer
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
The goal of this clinical research study is to test the accuracy of magnetic resonance elastogram (MRE) and 2-point dixon magnetic resonance imaging (2PD MRI) using new computer software (called "phase correction algorithm") in…
- Trial name
- NCT00543777
- Testing
- Magnetic Resonance Elastogram, 2-Point Dixon Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Non-alcoholic Fatty Liver Disease (NAFLD)
Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD
To assess the effect of a methionine metabolism-based dietary strategy in patients with non-alcoholic fatty liver disease in order to reduce complications while improving the quality of life for patients.
- Trial name
- NCT04450875
- Testing
- Experimental group (with diet)
- Where
- Mexico
- Volunteers
- 121 people
- Sponsor
- Universidad Veracruzana
Cirrhosis, MASLD
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD
The Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of chronic liver disease globally, with a prevalence exceeding 30% in the population.
- Trial name
- NCT07249112
- Testing
- genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma
- Where
- Italy
- Volunteers
- 2,880 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Obesity, Weight Loss
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue.
- Conditions
- Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis
- Trial name
- NCT02933554
- Testing
- Embospheres Microspheres
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Keith Pereira, MD:
T2DM With NAFLD
AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
This is a phase I/IIa, randomized, single-blind, placebo-controlled, multiple-ascending dose study conducted at a single site. The study plans to include up to approximately 46 evaluable subjects with Type 2 Diabetes Mellitus…
- Trial name
- NCT02826525
- Testing
- AZD4076
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
The purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others.
- Conditions
- Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity
- Trial name
- NCT01104220
- Testing
- Weight loss
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Polycystic Liver Disease, Polycystic Hepatorenal Disease
Automatic Segmentation of Polycystic Liver
Assessing the volume of the liver before surgery, predicting the volume of liver remaining after surgery, detecting primary or secondary lesions in the liver parenchyma are common applications that require optimal detection of…
- Conditions
- Polycystic Liver Disease, Polycystic Hepatorenal Disease, Liver Injury
- Trial name
- ASEPOL (NCT03960710)
- Testing
- Anonymized CT examinations, Training (1), Training (2)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Total Parenteral Nutrition-induced Cholestasis
Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition
Patients who are not able to eat normally for a longer time require parenteral nutrition, i.e. they receive liquids and nutrients directly into their veins. This can have many long-term side effects, including liver problems.
- Trial name
- NCT01565278
- Testing
- Soybean oil (Standard treatment), Soybean oil + Fish oil
- Where
- 4 sites in Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Johane Allard
Non-Alcoholic Fatty Liver Disease
Smartphone App for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a disease spectrum that encompasses excessive liver deposition of fat (NAFL), non-alcoholic steatohepatitis (NASH), and NASH cirrhosis.
- Trial name
- AppLiver (NCT05180760)
- Testing
- Smartphone app use, Standard of care
- Where
- China
- Volunteers
- 260 people
- Sponsor
- The University of Hong Kong
Non-alcoholic Steatohepatitis (NASH)
Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH
The primary objectives of this study are to evaluate the effect of ESG with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) compared to LSG on 1) histological improvement in NASH; 2) all-cause mortality and liver-related…
- Trial name
- TESLA-NASH (NCT04060368)
- Testing
- Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications, Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Fatty Liver, Nonalcoholic, Diet, Healthy
Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat
Excessive fat in the liver is associated with impairments in metabolic health. Reducing the amount of carbohydrates and fat both have been shown to reduce liver fat.
- Conditions
- Fatty Liver, Nonalcoholic, Diet, Healthy, Obesity
- Trial name
- NCT04054297
- Testing
- High GI/SFA diet, Low GI/SFA diet
- Where
- Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Gastrointestinal Neoplasms, Ovarian Neoplasms
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate…
- Trial name
- GCC0319 (NCT00390182)
- Testing
- Gemcitabine
- Where
- 2 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- University of Maryland, Baltimore
Non Alcoholic Fatty Liver Disease, Lifestyle
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
The study is an open-label intervention non pharmacological Cohort Study without control arm in patients with Non Alcoholic Fatty Liver Disease (NAFLD) and in healthy subjects.
- Conditions
- Non Alcoholic Fatty Liver Disease, Lifestyle, Diet Modification
- Trial name
- SEELN (NCT03300661)
- Testing
- Mediterranean Style
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Università degli Studi di Brescia
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
Objective Response Rate, Progression-free Survival
Real-world Study for Patients With Advanced Hepatobiliary Tumors
The investigators design a large sample size study in the real-world to explore whether targeted therapy and immunotherapy can improve the survival, quality of life and drug safety of patients with advanced hepatobiliary tumors…
- Conditions
- Objective Response Rate, Progression-free Survival, Overall Survival, Disease Control Rate
- Trial name
- NCT03892577
- Testing
- Precision oncology including targeted therapy and immunotherapy
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking Union Medical College Hospital
NAFLD, Obesity
Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)
Epidemiological data and studies in animal models suggest, that polyunsatured fatty acids (PUFA) rather than mono-unsatured fatty acids (MUFA) are associated with lower hepatic lipid content (HCL) and may facilitate a decrease of…
- Conditions
- NAFLD, Obesity, Prediabetes, Dyslipoproteinemia
- Trial name
- UFOP-2 (NCT02458586)
- Testing
- Dietary intervention / counseling
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- German Institute of Human Nutrition
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide.
- Trial name
- NAFLD-CARE (NCT04435054)
- Testing
- Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.